ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,3773
0,35%
Bitcoin
65.965,59
-1,01%
Brent Oil
82,18
0,07%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) Notícias

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:INDP
DataHoraFonteTítuloCódigoCompanhia
11/06/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies SummitNASDAQ:INDPIndaptus Therapeutics Inc
07/06/202418:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
07/06/202417:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/06/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
03/06/202409:00GlobeNewswire Inc.Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
30/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
29/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202409:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
08/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/04/202408:30GlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
28/03/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
25/03/202409:30GlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
18/03/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
13/03/202408:30GlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202409:30GlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
15/02/202410:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/02/202410:00GlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
04/01/202410:00GlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202318:01GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202310:00GlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202310:01GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingNASDAQ:INDPIndaptus Therapeutics Inc
27/09/202309:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the LD Micro Main Event XVINASDAQ:INDPIndaptus Therapeutics Inc
26/09/202309:00GlobeNewswire Inc.Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023NASDAQ:INDPIndaptus Therapeutics Inc
19/09/202309:00GlobeNewswire Inc.Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
06/09/202309:05GlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
14/08/202309:00GlobeNewswire Inc.Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
10/08/202309:45GlobeNewswire Inc.Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
07/08/202309:00GlobeNewswire Inc.Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical OfficerNASDAQ:INDPIndaptus Therapeutics Inc
15/06/202309:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:INDP

Seu Histórico Recente

BIT
UB7HQG
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados